



IFW

Attorney Docket No. 059490-5042-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Inventor(s): Anders PETTERSSON et al)	
)	
Appln. No. 10/531,598)	Group Art Unit: 1618
)	
Filed: November 25, 2005)	Examiner: Young, M.P.
)	
For: GASTRIC ACID SECRETION)	
INHIBITING COMPOSITION)	

POWER OF ATTORNEY BY ASSIGNEE

Commissioner of Patents and Trademarks
U.S. Patent and Trademark Office
Customer Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

I, Thomas Lundqvist, the Chief Innovation Officer of OREXO AB, certify that OREXO AB is the assignee of the entire right, title and interest in and to the subject application, which is a continuation of U.S. Appln. No. 09/787,898, by virtue of assignment by the inventors to Diabact AB recorded at Reel 011902, Frame 0952 and by name change of Diabact AB to OREXO AB, recorded on Reel 016618, Frame 0307.

As a duly authorized representative of the assignee OREXO of the above-referenced patent application, I hereby appoint Paul N. Kokulis, Reg. No. 16773 and the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to transact all business in the Patent and Trademark Office connected with said above-referenced application. All prior Powers are hereby withdrawn.


I further direct that all correspondence be addressed to said Customer Number 009629 at the address given below:

Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004

Please address all telephone inquiries to Paul N. Kokulis of said address at 202-739-5455.

Respectfully submitted,

OREXO AB

By: 
Name: Thomas Lundqvist
Title: Executive Vice-President and
Chief Innovation Officer

Date: June 1, 2007